Creative Commons source reading · Neurodegeneration biomarkers and longitudinal studies
Poor long-term outcomes and abnormal neurodegeneration biomarkers after military traumatic brain injury: the ADVANCE study.
Neil Sn Graham; Grace Blissitt; Karl Zimmerman; Lydia Orton; Daniel Friedland; Emma Coady; Rhiannon Laban; Elena Veleva; Amanda J Heslegrave; Henrik Zetterberg; Susie Schofield; Nicola T Fear; Christopher J Boos; Anthony M J Bull; Alexander Bennett; David J Sharp; ADVANCE Study
Originally published in Journal of neurology, neurosurgery, and psychiatry · 2025-01-16
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Traumatic brain injury (TBI) is common in military campaigns and is a risk factor for dementia. A rme D Ser V ices Tr A uma and Rehabilitatio N Out C om E -TBI (ADVANCE-TBI) aims to ascertain neurological outcomes in UK military personnel with major battlefield trauma, leveraging advances in quantification of axonal breakdown markers like neurofilament light (NfL), and astroglial marker glial fibrillar acidic protein (GFAP) in blood. We aimed to describe the causes, prevalence and consequences of TBI, and its fluid biomarker associations. Methods TBI history was ascertained in 1145 servicemen and veterans, of whom 579 had been exposed to major trauma. Functional and mental health assessments were administered, and blood samples were collected approximately 8 years postinjury, with plasma biomarkers quantified (n=1125) for NfL, GFAP, total tau, phospho-tau 181 , amyloid-β 42 and 40. Outcomes were related to neurotrauma exposure. Results TBI was present in 16.9% (n=98) of exposed participants, with 46.9% classified as mild-probable and 53.1% classified as moderate to severe.
Discussion
A substantial proportion (~17%) of participants with major combat trauma in the ADVANCE cohort experienced a TBI, of which around a third were moderate-to-severe. Neurotrauma was associated with greater extents of affective symptoms and worse quality of life, motor and employment outcomes. Plasma GFAP, a marker of glial activation, was significantly elevated an average of 8 years after the traumatic injury and increased levels were associated with a reduced likelihood of working.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
